PharmaPendium
Sanofi and DNDi drug approval
Support successful EMA and FDA submissions with drug-drug interaction predictions
PharmaPendium’s mechanistic static Drug-Drug Interaction Risk Calculator (DDIRC) identifies potential drug-drug interactions between a drug candidate and marketed drugs.
Sanofi/DNDi fexinidazole approval
Read about how Sanofi/DNDi used DDIRC predictions in its successful regulatory submissions for a new drug.
Download the full Sanofi/DNDi story
Key insights
- A complex metabolism pathway made it challenging to set up a dynamic approach (PBPK model).
- DDIRC identified potential drug interactions simultaneously, saving time and resources.
- DDIRC predictions supported the drug interactions sections of the labelling (SmPC and US PI).
Get all the details
Download the full customer story to read in Sanofi/DNDi’s own words about the DDIRC predictions that supported EMA and FDA authorization of fexinidazole.
Learn more about the DDIRC
To speak with a PharmaPendium representative about the DDIRC, please fill out the information requested below.